Effect of arsenic trioxide on cell cycle progression of cell line KBM5R with T315I point mutation

Journal of Jilin University Medicine Edition

Volumn 37, Issue 2, 2011, Pages 245-249

  Li, Xiao Feng ^a   Liu, Qiu Ju ^a   Li, Jing He ^a   Wang, Xiu Li ^a   Shen, Wei Zhang ^a   Lu, Ai Ping ^a   Jia, Bo ^b   Chen, Peng ^a  

^a JILIN UNIVERSITY   (China)

^b NONE

Author keywords

Arsenic trioxide; Cell cycle; Imatinib resistance; T315I point mutation

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ARSENIC TRIOXIDE; IMATINIB; ISOLEUCINE; PROTEIN P21; PROTEIN P27; THREONINE;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; INHIBITION KINETICS; POINT MUTATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; WILD TYPE;

EID: 79960247143     PISSN: 1671587X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Quintas-Cardama A, Cortes J. Molecular biology of BCR-ABL positive chronic myeloid leukemia [J]. Blood, 2009, 113(8): 1619-1630.
2. Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase [J]. Biologics, 2010, 2(4): 315-323.
3. Tanaka R, Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation [J]. Anticancer Ther, 2008, 8(9): 1387-1398.
4. Canestraro M, Galimberti S, Savli H, et al. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders [J]. Cancer Genet Cytogenet, 2010, 199(2): 110-120.
5. Lee PC, Kakadiya R, Su TL, et al. Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells [J]. Neoplasia, 2010, 12(5): 376-387.
6. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation and amplification [J]. Science, 2001, 293(5531): 876-880. (Pubitemid 32743979)
7. Kchour G, Tarhini M, Kooshyar MM, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL) [J]. Blood, 2009, 133(26): 6528-6532.
8. Perkins C, Kim CN, Fang GF, et al. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express BCR-ABL or overexpress MDR, MRP, Bcl-2, or Bcl-xL [J]. Blood, 2000, 95(3): 1014-1022. (Pubitemid 30062726)
9. Puccetti E, Guller S, Orleth A, et al. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity [J]. Cancer Res, 2000, 60(13): 3409-3413. (Pubitemid 30482156)
10. Gamet-Payrastre L, Li P, Lumeau S, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells [J]. Cancer Res, 2000, 60(5): 1426-1433. (Pubitemid 30152017)
11. Murray AW. Recycling the cell cycle: cyclins revisited [J]. Cell, 2004, 116(2): 221-234. (Pubitemid 38167314)